Anti-CD20 monoclonal antibodies in membranous nephropathy. (PubMed, Nefrologia (Engl Ed)) - Oct 4, 2026 - "Rituximab has long been the main monoclonal antibody used to treat immune-mediated glomerulopathies...Therefore, other drugs targeting the same therapeutic receptor, anti-CD20, have been developed. This review aims to highlight, from a comprehensive perspective, the different anti-CD20 agents available to date."
Journal • Review • B Cell Lymphoma • Glomerulonephritis • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Renal Disease
|
|
Arturo Villalobos Navarro; Avinash Chandu Nanwani; Eduardo Guerrero Hinzpeter; Enrique José Antonio Robiou Vivero; Juan Daniel Diaz-Garcia; Laurence H Beck; Luis Fernando Quintana
|